Clinical trials: ALK-Positive Large B-Cell Lymphoma
- Condition ALK-Positive Large B-Cell Lymphoma
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Anaplastic Lymphoma Kinase (ALK)- Positive Tumors, Non-small Cell Lung Cancer (NSCLC)
Managed Access Programs for LDK378, Ceritinib
The purpose of this registration is to list Managed Access Programs (MAPs) related to LDK378, Ceritinib.
- Trial name
- NCT05100134
- Testing
- ceritinib
- Sponsor
- Novartis Pharmaceuticals
Anaplastic Lymphoma Kinase Positive (ALK +) Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors
Pharmacokinetics, Safety, and Efficacy of Brigatinib Monotherapy in Pediatric and Young Adult Participants With ALK+ Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors or Other Solid Tumors
The purpose of this study is to estimate the maximum tolerated dose (MTD)/ recommended phase 2 dose (RP2D) regimen and characterize the pharmacokinetics (PK) of brigatinib monotherapy (film-coated tablets and age-appropriate…
- Conditions
- Anaplastic Lymphoma Kinase Positive (ALK +) Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors, Solid Tumors
- Trial name
- NCT04260009
- Testing
- Brigatinib, Brigatinib AAF
- Sponsor
- Takeda